US FDA approves Novartis Kesimpta (ofatumumab) for relapsing forms of MS treatment EP News Bureau Aug 21, 2020 Ofatumumab was first approved by the FDA in 2009 for the treatment of chronic lymphocytic leukaemia (CLL)
